Keywords
Treatment
Drugs
Immunomodulators
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To introduce the main therapeutic innovations, including the use of immunomodulatory agents to improve the efficacy of treatment for pulmonary tuberculosis. Literature Review: The treatment of tuberculosis remains a public health challenge, especially to attain a cure and a rapid reduction in the transmission of the disease. Chemoprophylaxis regimens aim to prevent infection as well as halt the development of the disease in tuberculosis-infected individuals. The use of chemical agents to enhance the host's regulatory immune response to Mycobacterium tuberculosis is an interesting approach to reduce the risk of drug resistance and clinical complications. Immunomodulators are substances that act on the immune system by potentiating immune responses against infectious microorganisms, and have shown immunotherapeutic effects against TB. New drugs for tuberculosis include phytopharmaceuticals, phytocomplexes, and reused drugs, which even target resistant strains of the pathogen, and are important options for the treatment of this disease. Final Considerations: Reused drugs, phytopharmaceuticals, new drugs under study, and immunomodulators are viable options to maximize the treatment of pulmonary tuberculosis and improve treatment adherence with less toxic measures than current treatment.
References
AGUIAR FS, DE QUEIROZ MELLO FC. Latent tuberculosis and the use of immunomodulatory agents. Jornal Brasileiro de Pneumologia Sociedade Brasileira de Pneumologia e Tisiologia, 2019; 45(2).
ALLUÉ-GUARDIA A, et al. Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis. International Journal of Molecular Sciences, 2021; 22(2): 735-739.
ARBEX MA, et al. Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais - Parte 1: fármacos de primeira linha. Jornal Brasileiro de Pneumologia, 2010; 36(5): 626–640.
ARBEX MA, et al. Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais- Parte 2: fármacos de segunda linha. Jornal Brasileiro de Pneumologia, 2010; 36(5): 641–656.
ARBEX MA, et al. O desafio do tratamento da tuberculose extensivamente resistente em um hospital de referência no estado de São Paulo: Um relato de três casos. Jornal Brasileiro de Pneumologia, 2015; 41(6): 554–559.
BEHR MA, et al. Latent tuberculosis: Two centuries of confusion. American Journal of Respiratory and Critical Care Medicine. American Thoracic Society, 2021; 204(4):142-148.
CONRADIE F, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. New England Journal of Medicine, 2020; 382(10):893–902.
DE FARIA R. et al. Perfil de resistência à antimicrobianos da classe dos Beta-lactâmicos e Aminoglicosídeos em cepas de Escherichia coli isoladas entre janeiro de 2015 e dezembro de 2018 / Antimicrobial resistance profile of the Beta-lactams and Aminoglycosides class in Escherichia coli strains isolated between january 2015 and december 2018. Brazilian Journal of Development, 2022; 8 (7):51673–51691.
FATIMA S, BHASKAR A, DWIVEDI VP. Repurposing Immunomodulatory Drugs to Combat Tuberculosis. Frontiers in Immunology, 2021;12:645485
FERNANDES GFS, SANTOS JL. Planejamento, síntese e avaliação anti-Mycobacterium tuberculosis de novos derivados benzofuroxanos e nitroimidazooxazinas úteis para o tratamento da tuberculose multirresistente. Tese de Doutorado (Química- IQ). UNESP, [S. l.], 2021. Disponível em: https://bv.fapesp.br/pt/dissertacoes-teses
FERREIRA NETO PTP, TELLIS CJM, PIMENTA FP. Novos Derivados de Plantas Medicinais para Tratamento da Tuberculose em Documentos de Patente. Cadernos de Prospecção, 2022; 15(1): 275–290.
GILMAR GJ, et al. Tuberculose: aspectos gerais e desenvolvimento de novas vacinas tuberculosis: general aspects and development of new vaccines. SaBios-Revista de Saúde e Biologia, 2020; 15(3): 82–92.
HUAMAN MA, STERLING TR. Treatment of Latent Tuberculosis Infection—An Update. Clinics in Chest Medicine, 2019; 40(4): 839–848.
INCERTI MK, et al. Reaproveitamento de medicamentos para o tratamento de pacientes acometidos pela Covid-19: uma estratégia rápida e eficaz para salvar vidas. Revista Saúde (Santa Maria), 2022; 48(1).
KATZUNG BG, TREVOR AJ. Farmacologia básica e clínica. 13 ed. Editora McGraw-Hill, 2017; 815-824.
LOPES DMA, PINHEIRO VGF, MONTEIRO HSA. Diagnosis and treatment of latent tuberculosis infection in patients undergoing treatment with immunobiologic agents: a four-year experience in an endemic area. J Bras Pneumol, 2019; 45(6): e20180225.
MAPHASA RE, MEYER M, DUBE A. The Macrophage Response to Mycobacterium tuberculosis and Opportunities for Autophagy Inducing Nanomedicines for Tuberculosis Therapy. Frontiers in Cellular and Infection Microbiology Frontiers Media S.A., 2021; 10: 618414.
MASSABNI AC, BONINI EH. Tuberculose: história e evolução dos tratamentos da doença. Revista Brasileira Multidisciplinar, 2019; 22(2): 6–34.
MI J, et al. The Research Progress in Immunotherapy of Tuberculosis. Frontiers in Cellular and Infection Microbiology Frontiers Media S.A., 2021; 11: 763591.
MINIAS A, et al. Early Drug Development and Evaluation of Putative Antitubercular Compounds in the Omics Era. Frontiers in Microbiology Frontiers Media S.A., 2021; 11: 618168.
NUNES H, et al. Incidência de tuberculose extrapulmonar. Rev Soc Bras Clin Med, 2019; 17(2):63-5.
PEETLUK LS, et al. Systematic review of prediction models for pulmonary tuberculosis treatment b outcomes in adults. BMJ Open, 2021; 11(3): e044687.
PINTO FG, et al. Adesão ao tratamento de tuberculose na Atenção Primária à Saúde: fatores favoráveis e desfavoráveis para esse processo. Research, Society and Development, 2022; 11(4): e3011426962.
RABAHI MF, et al. Tuberculosis treatment. Jornal Brasileiro de Pneumologia. Sociedade Brasileira de Pneumologia e Tisiologia, 2017; 43(6): 472-486.
RIBEIRO GD, BELFORT IKP. Programa De Acompanhamento Aos Pacientes Com Tuberculose.Repositório Faculdade Laboro, 2019; 315.
RAO MUVVA J, et al. Immunomodulatory Agents Combat Multidrug-Resistant Tuberculosis by Improving Antimicrobial Immunity. The Journal of Infectious Diseases, 2021; 224(2): 332–344.
SANTOS EF, et al. O Programa Nacional de Controle da Tuberculose (PNCT) tem uma dimensão escalar? Atas – Investigação Qualitativa em Saúde, 2019; 2.
SILVA DR, MELLO FCQ, MIGLIORI GB. Shortened tuberculosis treatment regimens: What is new? Jornal Brasileiro de Pneumologia, 2020; 46(2).
SINGH V, CHIBALE K. Strategies to Combat Multi-Drug Resistance in Tuberculosis. Accounts of Chemical Research, 2021; 54(10): 2361–2376.
SOTGIU G, et al. The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. Eur Respir J., 2016; 48(4): 963-971.
SUÁREZ I, et al. The Diagnosis and Treatment of Tuberculosis. Deutsches Ärzteblatt international, 2019; 116(43): 729–735.
YAO R, et al. Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis. Microbiology Spectrum, 2022; 10(1): e0247721.
ZHU B, et al. Tuberculosis vaccines: Opportunities and challenges. Respirology, 2018; 23(4): 359-368.